Fig. 1From: First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumorsPatient distribution. Abbreviation: EoT, end of treatment. *A total of 11 patients decided to discontinue the study treatment but were still kept in the study for disease progression and/or safety follow upBack to article page